---
title: "Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295960940.md"
description: "Oliver McCammon of LifeSci Capital reaffirmed a Buy rating on Inhibrx with a $230 price target ahead of key INBRX-106 Phase 2 readouts. He cites the upcoming HexAgon-HN trial data as a major catalyst, noting strong prior response rates and durability. The analyst highlights the company's focused pipeline, 1.7-year cash runway, and high short interest as creating an attractive risk-reward profile. Stifel Nicolaus also maintained a Buy rating with a higher $325 target."
datetime: "2026-08-14T17:15:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295960940.md)
  - [en](https://longbridge.com/en/news/295960940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295960940.md)
---

# Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Inhibrx Biosciences Inc, with a price target of $230.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Oliver McCammon has given his Buy rating due to a combination of factors tied to Inhibrx’s clinical and strategic positioning. He highlights the upcoming randomized progression-free survival readout from the HexAgon-HN Phase 2 trial of INBRX-106 plus pembrolizumab in frontline recurrent or metastatic head and neck cancer as a key potential catalyst, especially given prior overall response rate data that suggest meaningful incremental benefit over pembrolizumab alone.

He also views durability of response as critical for validating INBRX-106’s immuno-oncology mechanism and for differentiating it versus emerging EGFR bispecific approaches in the same setting. In addition, he considers the company’s focused pipeline, current cash runway of roughly 1.7 years, and the elevated short interest as creating an attractive risk‑reward profile, with the unchanged $230 price target reflecting his conviction that favorable upcoming data could drive substantial upside from current levels.

In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $325.00 price target.

### Related Stocks

- [INBX.US](https://longbridge.com/en/quote/INBX.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?](https://longbridge.com/en/news/296008452.md)
- [Inhibrx Biosciences Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295839677.md)
- [UBS Reaffirms Their Hold Rating on The Estée Lauder Companies (EL)](https://longbridge.com/en/news/296481710.md)
- [MA Financial Group Sticks to Its Buy Rating for Larvotto Resources Limited (LRV)](https://longbridge.com/en/news/296036753.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)